Safety of Effivia®, a Bevacizumab Biosimilar

Sponsor
Laboratorios Liomont
Study ID
NCT06313268
Status
Completed

Conditions

  • Metastatic Cervical Cancer
  • Metastatic Colorectal Cancer
  • Non Squamous Non Small Cell Lung Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

This is a post-marketing observational study aimed to evaluated the safety profile of Effivia®, a biosimilar of bevacizumab, in mexican patients with different types of cancer.

Key Dates

First listed
Mar 15, 2024
Start date
Aug 11, 2022
Status verified
Oct 2024
Primary completion
Apr 17, 2024
Completion
Sep 2, 2024

Study Design

Enrollment
83 participants (actual)

Arms

  • Arm: Test group
    Bevacizumab (Effivia®)

Primary Outcome Measure

Adverse events [ Time Frame: From date of patient inclusion to the end of Cycle 1 (each cycle is up to six months) ]

Related Studies